骨转移就会影响PD-1！

示同意和非商业。如该电脑系统信息被用以了解之外电脑系统大部份的目的，设站不应尽之外负起。

再三注意：

[1] Qiang H,et al. Pembrolizumab monotherapy or combination therapy for bone metastases in advanced non-small cell lung cancer: a real-world retrospective study. Transl Lung Cancer Res. 2022 Jan;11(1):87-99.

[2] Zhu YJ, et al. Bone metastasis attenuates efficacy of immune checkpoint inhibitors and displays "cold" immune characteristics in Non-small cell lung cancer. Lung Cancer. 2022 Apr;166:189-196.

[3] 张娣,等.PD-1/PD-L1致病检查点诱导剂在肝癌中就会的科学研究进展[J].中就会国肝癌华尔街日报,2019,22(06):369-379.

[4] 胡方正,罗佩金,薛涛.肝癌突转移前提的科学研究进展[J].南京大学学报(药学海外版),2021,40(05):714-720.

[5] Turpin A, , et al. Bone Metastasis: Current State of Play. Transl Oncol. 2020 Feb;13(2):308-320.

[6] Cao Y, Afzal MZ, Shirai K. Does denosumab offer survival benefits? -Our experience with denosumab in metastatic non-small cell lung cancer patients treated with immune-checkpoint inhibitors. J Thorac Dis. 2021 Aug;13(8):4668-4677.

[7]Schoenfeld AJ, et al. Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas. Ann Oncol. 2020 May;31(5):599-608.

[8]中就会国抗癌协就会恶性流行病学专业委员就会.中就会国非小细胞核肝癌PD－L1暗示测定临床流行病学专家学者一致[J].中就会华恶性华尔街日报,2020,42(07):513-521.

[9] Alexander Liede,et al. Dougall & Mark J. Smyth (2018) An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer, OncoImmunology, 7:12, e1480301

[10] S. Mangliti, et,al. #637 Bone-targeted agents improve survival in advanced non-small-cell-lung cancer patients with high bone tumor burden treated with immune-checkpoint inhibitors. 2021 World Conference on Lung Cancer. September 8-14, 2021.

[11]董智,等.肝癌突转移诊疗专家学者一致(2019海外版)[J].中就会国肝癌华尔街日报,2019,22(04):187-207.

本文转载自其他网站，不代表健康界观点和立场。如有内容和图片的商标权断然，再三及时关系我们（电话号码：guikequan@hmkx.cn）

。

奥美拉唑肠溶胶囊的作用
伤口愈合快吃什么药好
上海批准干细胞临床机构
金奥康奥美拉唑胶囊的作用与功效
手术后恢复
八子补肾胶囊
思密达与肠炎宁颗粒的区别
哪种家用血糖仪好
金笛如何治疗新冠
瑞特血糖仪和罗氏血糖仪哪个好